Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Endothelial NOS" patented technology

Endothelial NOS (eNOS), also known as nitric oxide synthase 3 (NOS3) or constitutive NOS (cNOS), is an enzyme that in humans is encoded by the NOS3 gene located in the 7q35-7q36 region of chromosome 7. This enzyme is one of three isoforms that synthesize nitric oxide (NO), a small gaseous and lipophilic molecule that participates in several biological processes. The other isoforms include neuronal nitric oxide synthase (nNOS), which is constitutively expressed in specific neurons of the brain and inducible nitric oxide synthase (iNOS), whose expression is typically induced in inflammatory diseases. eNOS is primarily responsible for the generation of NO in the vascular endothelium, a monolayer of flat cells lining the interior surface of blood vessels, at the interface between circulating blood in the lumen and the remainder of the vessel wall. NO produced by eNOS in the vascular endothelium plays crucial roles in regulating vascular tone, cellular proliferation, leukocyte adhesion, and platelet aggregation. Therefore, a functional eNOS is essential for a healthy cardiovascular system.

Magnetic erection device

The utility model relates to a low -cost magnetic erection device, and the device promotes the production of nitric oxide through endothelial nitric oxide synthase (eNOS) from endothelium, that is, the innermost layer of blood vessel structure, does not need contact and does not contain chemical substances when applying in vitro, increases the blood circulation of the tissue of application area, simultaneously provides the possibility of repeated use and portable use through its in vitro, promotes the blood vessel expansion of application area through pulsed electromagnetic field (PEMF), increases the synthesis of tissue growth factor (such as vascular endothelial growth factor), does not cause painful irritation, and can adjust power, frequency and duration.
Owner:SÜLEYMAN DEMİREL ÜNİVERSİTESİ İDARİ VE MALİ İŞLER DAİRE BAŞKANLIĞI GENEL SEKRETERLİK

A method for the in vitro diagnosis of the risk of occurrence of delayed cerebral ischemia following subarachnoid hemorrhage from a ruptured aneurysm as well as marker substances and the use thereof as a screening test

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.
Owner:UNIV MEDYCZNY W ODZI